Pharmaceutical composition and use thereof
AssigneeNational Taiwan National University
InventorJung-Yaw Lin
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition including a therapeutically efficient amount of a compound represented by formula (1), at least an anticancer agent, and a pharmaceutically acceptable carrier. The present invention further provides a use of the compound represented by formula (1) for the manufacture of a medicament for treating hepatocellular carcinoma.
Claims18
A pharmaceutical composition, comprising:
- a therapeutically efficient amount of a compound represented by formula (1),
- wherein
- R1 is H, hydroxy, or methyl;
- R2 is H, C1-C3alkyl, hydroxy, —CN or halogen;
- each of R3 and R4 is independently selected from the group consisting of H, C1-C3alkyl, hydroxy, —CN, and halogen;
- R5 is H, hydroxy or methyl;
- R6 is H, C1-C3alkyl, hydroxy, —CN, halogen, or —COOR11;
- and
- R7 is C1-C3alkyl or —COOR11, wherein Ru is H or C1-C3alkyl;
- at least a multikinase inhibitor, wherein the molar ratio of the compound and the at least a multikinase inhibitor in the pharmaceutical composition is from 2:1 to 1:32;
- and
- a pharmaceutically acceptable carrier.
A method of treating hepatocellular carcinoma and/or inhibiting proliferation or migration of hepatocellular carcinoma cells, comprising contacting the hepatocellular carcinoma and/or the hepatocellular carcinoma cells with a medicament comprising at least an anticancer agent and a compound represented by formula (1):
- wherein
- R1 is H, hydroxy, or methyl;
- R2 is H, C1-C3alkyl, hydroxy, —CN or halogen;
- each of R3 and R4 is independently selected from the group consisting of H, C1-C3alkyl, hydroxy, —CN, and halogen;
- R5 is H, hydroxy or methyl;
- R6 is H, C1-C3alkyl, hydroxy, —CN, halogen, or —COOR11;
- and
- R7 is C1-C3alkyl or —COOR11, wherein R11 is H or C1-C3alkyl.
A method of treating hepatocellular carcinoma and/or inhibiting proliferation or migration of hepatocellular carcinoma cells, comprising contacting the hepatocellular carcinoma and/or the hepatocellular carcinoma cells with a medicament comprising a compound represented by formula (2):
- wherein the medicament further comprises at least an anticancer agent, and the molar ratio of the compound represented by formula (2) and the at least an anticancer agent is from 2:1 to 1:32 in the medicament.
Dependencies are inferred from the claim text.